Place · Level 3 · Supplement
NMN / NR — NAD⁺ precursors
抗衰营销最响的赛道 · 池子下降 ≠ 前体不足 · CD38 才是凶手 · 人体硬终点 0 个
Story path
Chapter 1
NAD⁺ + 3 precursors
NAD⁺ + 3 precursors
nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. (nicotinamide adenine dinucleotide) is one of the busiest 'electron carriers' in cell metabolism. It accepts electrons in the ETC to become NADH (covered in niacin-b3/nad earlier), but NAD⁺ has a second role: enzyme-reaction substrate — once cleaved, it's gone and must be re-synthesized.
The body makes NAD⁺ via three main pathways:
De novo synthesis: tryptophan → quinolinic acid → NAD⁺ (slow, energy-expensive)Preiss-Handler: niacin (NA) → NaMN → NAD⁺ (the old drug niacin goes this way)Salvage: nicotinamide → NMN → NAD⁺ (NMN is the key intermediate of this path; NR is the stable precursor of NMN)
Relationship between NMN, NR, and NA:
NA (niacin) — FDA-approved lipid-lowering drug since 1955, 2–3 g large doses, real flushing / liver toxicity side effects but A-level evidenceNR (nicotinamide riboside) — Tru Niagen / Niagen, commercialized 2013, 200–1000 mg/dayNMN (nicotinamide mononucleotide) — Renue / Wonderfeel / various influencer brands, 250–1000 mg/day
All three eventually converge on the same NAD⁺ pool. But niacin runs $8/month while NMN runs $60–90/month — and that gap is one of the core stories to compare here.
The body makes NAD⁺ via three main pathways:
De novo synthesis: tryptophan → quinolinic acid → NAD⁺ (slow, energy-expensive)Preiss-Handler: niacin (NA) → NaMN → NAD⁺ (the old drug niacin goes this way)Salvage: nicotinamide → NMN → NAD⁺ (NMN is the key intermediate of this path; NR is the stable precursor of NMN)
Relationship between NMN, NR, and NA:
NA (niacin) — FDA-approved lipid-lowering drug since 1955, 2–3 g large doses, real flushing / liver toxicity side effects but A-level evidenceNR (nicotinamide riboside) — Tru Niagen / Niagen, commercialized 2013, 200–1000 mg/dayNMN (nicotinamide mononucleotide) — Renue / Wonderfeel / various influencer brands, 250–1000 mg/day
All three eventually converge on the same NAD⁺ pool. But niacin runs $8/month while NMN runs $60–90/month — and that gap is one of the core stories to compare here.
Why NAD⁺ falls with age
Massudi 2012 / Camacho-Pereira 2016 and others observed: in multiple human tissues, nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. falls about 50% from youth to old age. This is the starting point of the entire 'anti-aging NAD⁺ supplementation' market.But why it falls — the key isn't insufficient precursor:
Elderly people's dietary niacin / tryptophan don't suddenly run shortSalvage pathway enzyme activity doesn't drop obviously eitherWhat really rises is the consumption end — three downstream enzymes are eating NAD⁺:
1. Sirtuins (SIRT1-7) — the longevity gene family, 'restrained consumers'
2. PARP1/2 — emergency mobilizers for DNA damage
3. CD38 — age-related NADase, the main consumer, with expression / activity rising ~2-3× in old tissues (Camacho-Pereira 2016 *Cell Metab*, consistent across adipose, liver, muscle, and spleen)
Like 'pool water level dropping': it's not that the faucet slowed, it's that the drain at the bottom got bigger.
So: direct precursor supplementation can short-term raise the pool (Martens 2018: NR 1000 mg/day × 6 weeks raised blood NAD⁺ +60%), but as long as the consumption end is unchanged, within days to weeks the water level re-equilibrates — this logic is unpacked in detail in the next scene and L4.
Chapter 2
NAD⁺ consumers
NAD⁺ consumers
If you remember one thing about NMN/NR, remember this: the bottleneck of the nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. pool decline isn't precursors, it's consumers. Three enzymes are eating NAD⁺:
1. Sirtuins (SIRT1-7) — restrained type
Deacetylases; each acetyl group removed consumes one NAD⁺ → producing nicotinamide + 2'-O-acetyl-ADP-riboseThe longevity gene family (Sinclair lab favorite)Km is high ~150–200 µM, meaning they're sensitive to NAD⁺ concentration but not 'hungry'Restrained consumption — this is the basis of the 'supplement NAD⁺ → activate SIRT → extend lifespan' hypothesis
2. PARP1/2 — emergency gluttons
During DNA single- or double-strand breaks, PARP cleaves large amounts of NAD⁺ → attaching ADP-ribose chains to proteins at damage sites (PARylation)Each PARylation event consumes dozens to hundreds of NAD⁺, acute consumption rate 10–100 × SirtuinsUV light, oxidative stress, and chronic inflammation all continuously trigger thisElderly people accumulate more DNA damage → PARP works continuously → NAD⁺ is continuously burned
3. CD38 — the main age-related culprit
NAD glycohydrolase, cleaves NAD⁺ in one cut → nicotinamide + cyclic ADP-ribose (cADPR, a calcium-signaling molecule)CD38 expression rises with age; in old tissues its activity rises ~2-3× (Camacho-Pereira 2016 *Cell Metab*; consistent across adipose, liver, muscle, and spleen)The main explanation for age-related NAD⁺ decline — not precursor insufficiencyCD38 inhibitors (78c, apigenin, etc.) are a separate anti-aging research direction
Key insight: supplementing precursors raises inflow; CD38 is an enlarged drain. Without fixing both ends, the pool stays low.
Click 'Take a closer look at this scene →' for the 4-step animation.
1. Sirtuins (SIRT1-7) — restrained type
Deacetylases; each acetyl group removed consumes one NAD⁺ → producing nicotinamide + 2'-O-acetyl-ADP-riboseThe longevity gene family (Sinclair lab favorite)Km is high ~150–200 µM, meaning they're sensitive to NAD⁺ concentration but not 'hungry'Restrained consumption — this is the basis of the 'supplement NAD⁺ → activate SIRT → extend lifespan' hypothesis
2. PARP1/2 — emergency gluttons
During DNA single- or double-strand breaks, PARP cleaves large amounts of NAD⁺ → attaching ADP-ribose chains to proteins at damage sites (PARylation)Each PARylation event consumes dozens to hundreds of NAD⁺, acute consumption rate 10–100 × SirtuinsUV light, oxidative stress, and chronic inflammation all continuously trigger thisElderly people accumulate more DNA damage → PARP works continuously → NAD⁺ is continuously burned
3. CD38 — the main age-related culprit
NAD glycohydrolase, cleaves NAD⁺ in one cut → nicotinamide + cyclic ADP-ribose (cADPR, a calcium-signaling molecule)CD38 expression rises with age; in old tissues its activity rises ~2-3× (Camacho-Pereira 2016 *Cell Metab*; consistent across adipose, liver, muscle, and spleen)The main explanation for age-related NAD⁺ decline — not precursor insufficiencyCD38 inhibitors (78c, apigenin, etc.) are a separate anti-aging research direction
Key insight: supplementing precursors raises inflow; CD38 is an enlarged drain. Without fixing both ends, the pool stays low.
Click 'Take a closer look at this scene →' for the 4-step animation.
Precursor + CD38 inhibitor stack
If the logic above is right, the truly potentially effective anti-aging strategy isn't pure NMN/NR supplementation, it's: precursor (NR/NMN) + simultaneous CD38 inhibition.A few research directions:
78c: experimental CD38 inhibitor; in mouse aging models it restores the NAD⁺ pool and improves metabolism (Tarragó 2018 Cell Metab)Apigenin: natural flavonoid in celery / parsley; inhibits CD38 in vitro, but oral doses are far below human-effective levelsLuteolinidin / quercetin: weak in vitro CD38 inhibitors
This is why some researchers hold a mild skepticism toward NMN/NR alone — it's like adding water to a leaky bathtub without patching the leak.
Reality: nobody sells a 'leak-repair solution' on the market because there's no FDA-approved safe human CD38 inhibitor yet. So everything you see at CVS or iHerb is a 'water adder' — precursor-class supplements.
This doesn't mean NMN/NR are completely useless. Short-term raising of the nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. pool is real, and there are some small, limited, surrogate-endpoint signals (next scene). But marketing it as 'reversing aging' doesn't stand mechanistically.
Chapter 3
Marketing arc
Marketing arc
David Sinclair — Harvard geneticist and author of *Lifespan* — is the gravitational center of the NMN/NR market. He's an excellent biologist and also an excellent marketer, and the overlap of those two identities generates a lot of confusion.
At several key moments, the academic signal and the commercial narrative don't align — going point by point:
1. NMN rejuvenates mice?
Mills 2016 Cell Metab: mice given oral NMN 300 mg/kg daily for 12 monthsAging markers improved, insulin sensitivity rose, body weight maintainedNot rejuvenation, not significant lifespan extension (the study design wasn't powered for that)Media translation: 'Harvard scientists discover longevity molecule'Mouse dose translated to a 75 kg human ≈ 1800 mg/day — far above most commercial NMN doses
2. Sirtuins = longevity genes?
Early yeast SIR2 / worm sir-2 experiments showed caloric restriction activates Sirtuins → extends lifespanFollow-up replication studies (Burnett 2011 Nature) substantially weakened the effect, with several original papers receiving correctionsThe 'Sirtuin hypothesis' has been downgraded in scientific circles, but the commercial narrative continues using it
3. Joe Rogan / Andrew Huberman push
Joe Rogan 2019 podcast long-interview with Sinclair → overnight Tru Niagen / various NMN brands surged in salesAndrew Huberman subsequently recommended NRThis is the template of supplement marketing in the podcast era: one celebrity scientist + one celebrity host = millions of orders
4. Sinclair's personal interest conflicts
Founded Sirtris (acquired by GSK for $720M, later failed)Founded Life Biosciences / MetroBiotech (NMN commercial development)These relationships aren't violations, but should be known before purchase decisions
Worth remembering: 'Harvard's David Sinclair recommends it' isn't clinical evidence; it's name recognition, not an evidence base.
At several key moments, the academic signal and the commercial narrative don't align — going point by point:
1. NMN rejuvenates mice?
Mills 2016 Cell Metab: mice given oral NMN 300 mg/kg daily for 12 monthsAging markers improved, insulin sensitivity rose, body weight maintainedNot rejuvenation, not significant lifespan extension (the study design wasn't powered for that)Media translation: 'Harvard scientists discover longevity molecule'Mouse dose translated to a 75 kg human ≈ 1800 mg/day — far above most commercial NMN doses
2. Sirtuins = longevity genes?
Early yeast SIR2 / worm sir-2 experiments showed caloric restriction activates Sirtuins → extends lifespanFollow-up replication studies (Burnett 2011 Nature) substantially weakened the effect, with several original papers receiving correctionsThe 'Sirtuin hypothesis' has been downgraded in scientific circles, but the commercial narrative continues using it
3. Joe Rogan / Andrew Huberman push
Joe Rogan 2019 podcast long-interview with Sinclair → overnight Tru Niagen / various NMN brands surged in salesAndrew Huberman subsequently recommended NRThis is the template of supplement marketing in the podcast era: one celebrity scientist + one celebrity host = millions of orders
4. Sinclair's personal interest conflicts
Founded Sirtris (acquired by GSK for $720M, later failed)Founded Life Biosciences / MetroBiotech (NMN commercial development)These relationships aren't violations, but should be known before purchase decisions
Worth remembering: 'Harvard's David Sinclair recommends it' isn't clinical evidence; it's name recognition, not an evidence base.
Brand wars
Main players on the market:NR camp:
Tru Niagen / ChromaDex — the only NR product with FDA NDI (New Dietary Ingredient) acknowledgment, $30–40/month (300 mg)Several NR generic brands
NMN camp:
Wonderfeel — Sinclair-advised, $50–90/monthRenue / ProHealth / DoNotAge — $40–70/monthChinese white-label imports in volume (NMN production cost in China is now very low, ~$200/kg bulk), but purity varies widely
Quality risks:
2022 NSF audits found some NMN products contained less than 50% of label claimNMN is unstable at room temperature, degrading quickly with moisture / lightFDA 2022 issued a warning letter: NMN, because of an active drug trial (Metro Biotech's MIB-626) under review, no longer qualifies as a dietary supplement under the law — but enforcement hasn't followed and the market keeps running
You may not be buying what you think you're buying: this rule always applies, and applies especially in 'fashionable mechanism + ambiguous regulation' lanes.
In contrast, niacin (NA) is FDA-regulated, dose-stable, and 10× cheaper — and it goes through Preiss-Handler to ultimately raise the same nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. pool.
Chapter 4
Clinical RCTs
Clinical RCTs
Real status of human NMN/NR RCTs — and a wide gulf between this and 'reversing aging':
Martens 2018 Nat Commun (NR, n=24, healthy 55–79 years)
1000 mg/day NR × 6 weeks, double-blind crossoverBlood NAD⁺ +60% ✓ (mechanism level holds)Systolic BP −10 mmHg — but only in the hypertensive subgroup; primary analysis had no significant differenceExercise performance / lipids / inflammatory markers / insulin sensitivity: no difference
Yoshino 2021 Science (NMN, n=25, postmenopausal pre-diabetic women)
250 mg/day NMN × 10 weeks, double-blindMuscle insulin sensitivity +25% (P=0.048) ✓Whole-body insulin sensitivity / body fat / lipids / BP / cardiopulmonary function: no differenceSmall sample size, single endpoint significant
Igarashi 2022 (NMN, n=42, elderly men)
250 mg/day × 12 weeksModest gait speed / grip strength improvementNo mortality / cognitive / cardiovascular hard endpoints
Conze 2019 Sci Rep (NR, n=140 healthy overweight adults)
100–1000 mg/day × 8 weeks, safety + pharmacokineticsGood safety ✓No metabolic / performance endpoint improvement
No human RCT currently shows NMN/NR:
Extends lifespan ✗Prevents cancer / cardiovascular events / dementia ✗Meaningfully improves performance / strength / cognition ✗
What there is: raising the nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. pool (mechanism ✓) + a few small signals on surrogate endpoints (B-level evidence).
This is C-grade → B-grade evidence, not A-grade. The marketing rhetoric uses 'mechanism persuasion + mouse success + Harvard endorsement', not hard-endpoint RCTs.
Martens 2018 Nat Commun (NR, n=24, healthy 55–79 years)
1000 mg/day NR × 6 weeks, double-blind crossoverBlood NAD⁺ +60% ✓ (mechanism level holds)Systolic BP −10 mmHg — but only in the hypertensive subgroup; primary analysis had no significant differenceExercise performance / lipids / inflammatory markers / insulin sensitivity: no difference
Yoshino 2021 Science (NMN, n=25, postmenopausal pre-diabetic women)
250 mg/day NMN × 10 weeks, double-blindMuscle insulin sensitivity +25% (P=0.048) ✓Whole-body insulin sensitivity / body fat / lipids / BP / cardiopulmonary function: no differenceSmall sample size, single endpoint significant
Igarashi 2022 (NMN, n=42, elderly men)
250 mg/day × 12 weeksModest gait speed / grip strength improvementNo mortality / cognitive / cardiovascular hard endpoints
Conze 2019 Sci Rep (NR, n=140 healthy overweight adults)
100–1000 mg/day × 8 weeks, safety + pharmacokineticsGood safety ✓No metabolic / performance endpoint improvement
No human RCT currently shows NMN/NR:
Extends lifespan ✗Prevents cancer / cardiovascular events / dementia ✗Meaningfully improves performance / strength / cognition ✗
What there is: raising the nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. pool (mechanism ✓) + a few small signals on surrogate endpoints (B-level evidence).
This is C-grade → B-grade evidence, not A-grade. The marketing rhetoric uses 'mechanism persuasion + mouse success + Harvard endorsement', not hard-endpoint RCTs.
Why no large hard-endpoint trial
Why no large RCT? This itself is worth thinking about:1. Endpoints are too far away
Lifespan endpoint needs 10–20 years of follow-up + n in the thousandsCardiovascular hard endpoint needs n in thousands + 3–5 yearsThis scale of RCT is beyond a single company ($50–200M each)
2. Nobody will run this trial
On the FDA path, NMN is a supplement not a drug → manufacturers have no motive to run hard-endpoint trialsAcademic-led would need NIH / Wellcome funding → no large grant yetThe only one running is Metro Biotech's MIB-626 (drug path); if it succeeds, NMN stops being a supplement
3. Compare with drugs:
Statins: dozens of cardiovascular hard-endpoint RCTs, n=100,000+, all-cause mortality −10–20%Metformin (TAME trial): 6000+ elderly lifespan endpoint, still ongoingNMN/NR: none
So when reading NMN/NR claims, understand:
'Blood nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. +60%' is a mechanistic signal, not a health endpoint'Elderly mouse improvement' is a preclinical signal, not human evidence'David Sinclair takes it daily himself' is an anecdote / signal, not an RCT
None of this means it must be ineffective — it just means the current evidence level doesn't match the marketing intensity. This lane is worth tracking, but not worth all-in betting.
Chapter 5
Decision + niacin trump
Decision + niacin trump
The most counterintuitive fact: same nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. pool — niacin (NA) via Preiss-Handler and NR / NMN via salvage both fill it. But prices differ 10×.
Monthly price comparison (effective doses):
Decision tree:
Q1 What's your goal?
'Longevity / anti-aging / dementia prevention' → no human hard-endpoint evidence, not priority; spend money on sleep / exercise / nutrition / weight / not smoking for far higher ROI'Lipid improvement' → Niacin 2–3 g is FDA-approved prescription / OTC, A-level evidence. But has flushing / liver toxicity; prescriber guidance needed'Insulin resistance / pre-diabetes' → metformin (Rx, A) > weight management / exercise (A) > Berberine (B) > NMN (Yoshino 2021 B-grade, single endpoint)'Just want to try raising NAD⁺' → niacin 500 mg × 2 is cheapest; NR is mid-tier; NMN has the highest marketing premium
Q2 What risk can you tolerate?
Niacin: flushing (90% on first use, develops tolerance), liver toxicity (large doses), blood-sugar disturbanceNR / NMN: good short-term safety data (Conze 2019), long-term unknown
Q3 What do you trust?
FDA-regulated prescription drug → niacin (~$8/month)FDA NDI-accepted supplement → NR / Tru Niagen ($30–40/month)Ambiguous legal status but 'fashionable mechanism' → NMN ($60–90/month)
Worth remembering: when a marketing narrative tells you 'supplement X reverses aging' while a 10× cheaper old drug (niacin) in the same pathway goes unmentioned — that itself is a marketing-level signal.
Monthly price comparison (effective doses):
| Choice | Dose | Monthly cost | Regulation | Evidence level (NAD⁺ rise) |
|---|---|---|---|---|
| Niacin (CVS) | 500 mg × 2 | $8 | FDA-approved lipid drug | A (clear mechanism) |
| NR (Tru Niagen) | 300 mg | $30–40 | FDA NDI accepted | B (Martens 2018) |
| NMN (Renue/Wonderfeel) | 500 mg | $60–90 | Legal status ambiguous | B (Yoshino 2021) |
Decision tree:
Q1 What's your goal?
'Longevity / anti-aging / dementia prevention' → no human hard-endpoint evidence, not priority; spend money on sleep / exercise / nutrition / weight / not smoking for far higher ROI'Lipid improvement' → Niacin 2–3 g is FDA-approved prescription / OTC, A-level evidence. But has flushing / liver toxicity; prescriber guidance needed'Insulin resistance / pre-diabetes' → metformin (Rx, A) > weight management / exercise (A) > Berberine (B) > NMN (Yoshino 2021 B-grade, single endpoint)'Just want to try raising NAD⁺' → niacin 500 mg × 2 is cheapest; NR is mid-tier; NMN has the highest marketing premium
Q2 What risk can you tolerate?
Niacin: flushing (90% on first use, develops tolerance), liver toxicity (large doses), blood-sugar disturbanceNR / NMN: good short-term safety data (Conze 2019), long-term unknown
Q3 What do you trust?
FDA-regulated prescription drug → niacin (~$8/month)FDA NDI-accepted supplement → NR / Tru Niagen ($30–40/month)Ambiguous legal status but 'fashionable mechanism' → NMN ($60–90/month)
Worth remembering: when a marketing narrative tells you 'supplement X reverses aging' while a 10× cheaper old drug (niacin) in the same pathway goes unmentioned — that itself is a marketing-level signal.
5 should-skip groups + NAD test reading
5 groups that shouldn't supplement NMN/NR:1. Tight budget: the same money spent on sleep + nutrition + exercise gear has 100× the ROI
2. Under cancer screening / chemotherapy / radiation: nicotinamide adenine dinucleotide: A coenzyme that ferries electrons to drive energy production — built from vitamin B3. is a central tumor-metabolism substrate, may promote tumor growth (a real mechanistic risk); your oncologist hasn't told you 'you must supplement'
3. Chronic inflammation / autoimmune disease: PARP / CD38 elevation moves with inflammation, supplementing precursors may amplify certain pathways; data unclear
4. Pregnant / lactating: no human data, skip
5. Thinking 'anti-aging' while still staying up late + not exercising + smoking + sitting all day: your bottleneck isn't NAD⁺
On NAD⁺ blood tests:
Jinfiniti / NAD Quest / Tru Niagen etc. sell $200–500 blood NAD⁺ testsReal data? Partially real: NAD⁺ levels differ widely across tissues (liver / muscle / brain); blood NAD⁺ doesn't fully reflect tissue levelsTests low: doesn't necessarily mean you need NMN/NR; could be high CD38 / chronic inflammation / sleep deprivationTests high: doesn't necessarily mean 'anti-aging success'; could be tissue pool depletion (pathological state)In most cases, these tests are carefully designed marketing funnels — test low → you need to supplement → keep testing → keep paying
The cheapest reliable 'test': your sleep quality, morning energy, exercise recovery speed, and HRV — these reflect overall mitochondrial state and indirectly NAD⁺ utilization. Improving these is more useful than measuring NAD⁺.